Letter from FDA

To endorse/forward to the Bureau of Internal Revenue the updates to the list of VAT-exempt drugs and medicines under RA 11534 (CREATE), prepared by the FDA pursuant to the JAO VAT-exemption guidelines and DOH Department Memorandum routing for COVID-19 items.

Bureau of Internal RevenueIndependent research copy

Document type: DOC
Index unit: bir-text-letter-from-fda
Year: Not classified
Text quality: Not specified

Document text

Reference copy · verify against the official source

An OCR-degraded letter, apparently from the Food and Drug Administration under the Department of Health, addressed to the BIR Commissioner, transmits updates to the 'List of VAT-Exempt Drugs for Hypertension, Cancer, Mental Illnesses, Tuberculosis, Kidney Diseases, Diabetes, and High Cholesterol' issued pursuant to Republic Act (RA) 11534 (CREATE). It cites the VAT-exemption implementing guidelines in JAO No. 2-2018 and JAO No. 2021-0001, and DOH Department Memorandum No. 2021-0280, which routes documents on the VAT-exempt list of COVID-19-related medicines and medical devices to the FDA. Updates under 'For Inclusion' cover medicines for COVID-19 treatment (Enoxaparin Sodium injections) and hypertension (isosorbide dinitrate and isosorbide-5-mononitrate formulations). Names, numbers and dates are reconstructed from garbled text and the document is truncated.